Oncolytic Adenovirus for treatment of Canine Osteosarcoma

Background

Osteosarcoma is a highly aggressive mesenchymal bone malignancy that predominantly strikes children and young adults. Despite various medical advancements over the past four decades, the survival rates for patients with this disease have remained stubbornly stagnant. This lack of progress is particularly devastating for patients diagnosed with metastatic cases, where traditional treatment modalities frequently fail to halt disease progression. Consequently, there is a critical and urgent clinical need to develop novel therapeutic strategies that can effectively eradicate these resilient malignant cells and improve long-term patient outcomes.

While modern immunotherapies, specifically immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway, offer promising theoretical potential for treating such malignancies, current clinical applications face severe limitations. The primary problem with existing systemic administration of these checkpoint inhibitors is the induction of widespread, severe systemic toxicities that can endanger the patient. Furthermore, these conventional immunotherapeutic agents suffer from notoriously poor penetration into the dense, restrictive tumor microenvironment. The physical and immunosuppressive barriers of solid bone tumors prevent adequate concentrations of the therapeutic agents from reaching the core of the malignancy, ultimately rendering the systemic immune blockade ineffective at the actual disease site.

Technology

CAV2-AU-M3 is a conditionally replicative oncolytic adenovirus engineered to target and destroy canine osteosarcoma cells. A primary feature of this viral vector is its fiber protein, modified with an RGD motif to significantly enhance cellular entry. Once inside the tumor, the solution employs a dual-action mechanism. It selectively replicates within and lyses the osteosarcoma cells while simultaneously utilizing a specialized transgene cassette to express and secrete a functional anti-PD1 heavy chain antibody. This enables the virus to act as a localized factory for therapeutic antibodies while actively destroying the tumor.

This technology is highly differentiated because it overcomes the severe limitations of traditional systemic immunotherapies, namely poor tumor penetration and high systemic toxicity. By localizing the production of the anti-PD1 antibody directly within the tumor microenvironment, the solution maximizes immune checkpoint blockade where it is needed most while minimizing harmful systemic exposure. Furthermore, the synergistic combination of direct viral oncolysis and localized immune stimulation creates a highly effective anti-tumor response. Notably, the virus maintains robust antibody secretion even in replication-resistant tumor cells, ensuring consistent therapeutic delivery and offering a safer alternative to conventional checkpoint inhibitors.

Benefits

• Delivers a dual-action therapeutic approach by combining direct viral destruction (oncolysis) of osteosarcoma cells with localized immune checkpoint blockade.
• Minimizes systemic toxicity by producing and secreting anti-PD1 antibodies directly within the tumor microenvironment rather than throughout the entire body.
• Enhances viral entry and penetration into target cancer cells utilizing an engineered RGD fiber modification.
• Restores anti-tumor immunity by effectively blocking the PD-1/PD-L1 pathway and reversing T-cell exhaustion.
• Functions as a reliable local expression vector, maintaining robust therapeutic antibody production even in tumor cells that are resistant to direct viral lysis.
• Demonstrates significant tumor suppression and cytotoxicity across 2D cultures, 3D multicellular spheroids, and in vivo models.

Applications

• Veterinary osteosarcoma treatment
• Localized tumor immunotherapy delivery
• Targeted oncolytic viral therapy
• Pediatric osteosarcoma translational research
• Localized immune checkpoint blockade

Additional info

CAV2-AU-M3 is a conditionally replicative canine adenovirus type 2 variant engineered to target osteosarcoma. It features an RGD-modified fiber protein for integrin-mediated entry and encodes a secretory anti-PD1 heavy chain antibody under a CMV promoter. This platform combines direct viral oncolysis with localized immune checkpoint blockade, secreting functional antibodies that disrupt the PD-1/PD-L1 pathway to stimulate anti-tumor immunity within the microenvironment.